Scholars@Duke
Ara Dickran Metjian

Ara Dickran Metjian

Instructor in the Department of Medicine
Medicine, Hematology
ara.metjian@duke.edu
Duke Box 3422, Duke University Medical Center, Durham, NC 27710
0547 Stead Building, 100 Trent Drive, Durham, NC 27710

Selected Publications

Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome.

Journal Article Blood · September 12, 2024 In the 100 years since Eli Moschcowitz reported the first case of thrombotic thrombocytopenic purpura (TTP), there has been remarkable awareness and progress in the diagnosis and management of this rare blood disorder. This progress initially was the resul ... Full text Link to item Cite

A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura

Journal Article Research and Practice in Thrombosis and Haemostasis · March 1, 2024 Background: Mortality due to immune-mediated thrombotic thrombocytopenic purpura (iTTP) remains significant. Predicting mortality risk may potentially help individualize treatment. The French Thrombotic Microangiopathy (TMA) Reference Score has not been ex ... Full text Cite

Real-world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: A non-interventional, post-authorization safety study.

Journal Article Haemophilia · September 2023 INTRODUCTION: Recombinant porcine factor VIII (rpFVIII, susoctocog alfa) is indicated for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). AIM: To provide long-term real-world safety and effectiveness data for rpFVIII in the ... Full text Link to item Cite

iTTP: more long-term consequences.

Journal Article Blood · January 19, 2023 Full text Link to item Cite

Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study.

Journal Article J Thromb Haemost · December 2022 INTRODUCTION: Caplacizumab demonstrated efficacy and safety in patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) in the phase 3 HERCULES trial. However, data on long-term outcomes following caplacizumab treatment are limited. OBJECTI ... Full text Link to item Cite

Race, rituximab, and relapse in TTP.

Journal Article Blood · September 22, 2022 Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is characterized by recurring episodes of thrombotic microangiopathy, causing ischemic organ impairment. Black patients are overrepresented in iTTP cohorts in the United States, but racial disparit ... Full text Link to item Cite

Safety and tolerability of solvent/detergent-treated plasma for pediatric patients requiring therapeutic plasma exchange: An open-label, multicenter, postmarketing study.

Journal Article Transfusion · February 2022 BACKGROUND: This study investigated the real-world safety and tolerability of solvent/detergent-treated (S/D) plasma for pediatric patients requiring therapeutic plasma exchange (TPE). STUDY DESIGN AND METHODS: LAS-213 was a multicenter, open-label, interv ... Full text Link to item Cite

Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis.

Journal Article Blood Adv · April 27, 2021 The efficacy and safety of caplacizumab in individuals with acquired thrombotic thrombocytopenic purpura (aTTP) have been established in the phase 2 TITAN and phase 3 HERCULES trials. Integrated analysis of data from both trials was conducted to increase s ... Full text Link to item Cite

Ex vivo assays to detect complement activation in complementopathies.

Journal Article Clin Immunol · December 2020 In complement-driven thrombotic microangiopathies, failure to regulate complement activation leads to end-organ damage. The modified Ham (mHam) test measures complement-mediated killing of a nucleated cell in vitro but lacks a confirmatory assay and reliab ... Full text Link to item Cite

Hematology

Chapter · January 1, 2011 Full text Cite